The news directly mentions Nevro and the lowered price target by Citigroup analyst Joanne Wuensch. This may cause some investors to reconsider their positions, but the Neutral rating suggests that the stock is not expected to significantly outperform or underperform the market in the short term. Therefore, the short-term impact on the stock price is likely to be neutral.